“…It has been associated with severe gastrointestinal adverse events, gallbladder-related disorders, and hepatobiliary disorders ( 3 , 7 ). There have been also some reports of rare adverse events including hyperglycemia, acute pancreatitis, and acute nephritis ( 5 , 8 , 9 ). In the global phase 3 Semaglutide Treatment Effect in People with Obesity (STEP) program, no difference was found between semaglutide and placebo regarding psychiatric adverse effects ( 3 ).…”